92results about "Skeletal disorder" patented technology

The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

The invention discloses a Chinese material medical preparation, which cures orthopedic disorders and is made by olibanum, myrrh, ground beeltle, natural copper, pseudoginseng, safflower, knotweed, peach seed, eucommia bark, angelica and pawpaw through Chinese traditional medicine processing technique. The invention mainly cure the orthopaedics diseases of lumbar and shoulder projection, hyperosteogeny, cervical spondylosis, periarthritis humeroscapularis, arthritis, rheumatoid arthritis, old fracture and tenosynovitis, etc. The invention uses pure Chinese medicinal herb to make chemical preparation, has small toxic and side effect and obvious healing effect, and addresses both the symptoms and root causes, moreover, the clinical symptoms are rapid to eliminate, and have no rebound phenomenon after healing.

A method of improving the resistance of collagenous tissue subject to elevated collagenous tissue stress as a result of tissue removing surgical decompression surgery, comprising contacting at least a portion of the remaining collagenous tissue with an effective amount of a crosslinking reagent.

The invention discloses an external-use medicine for treating neck, shoulder, waist and leg diseases and osteoproliferation, and a preparation method of the medicine. The external-use medicine comprises active ingredients in parts by weight as shown in the description. The preparation method of the external-use medicine comprises the steps of wine soaking, drying, crushing, stirring, packaging and the like. The external-use medicine is completely prepared from traditional Chinese medicines and has the effects of warming channel, activating blood circulation, expelling wind, removing dampness, relieving swelling and pain, invigorating qi and blood, promoting blood circulation to remove blood stasis, tonifying kidney and strengthening du meridian. The external-use medicine has the advantages of good treatment effect, fast curative effect, very low toxicity, convenience in use and no limitation for treatment of the neck, shoulder, waist and leg diseases and the osteoproliferation. The preparation method is simple. The external-use medicine can be prepared into medicine packages which can be applied to home health care and medical treatment and are easy to carry.

Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with and responsive to modulation of the CB1 and/or CB2 receptor activity.

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

Compositions are provided comprising a family of peptides having binding specificity for bone, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to bone, and are used in methods related to bone implants, bone repair, and bone-related diseases.

The invention relates to Cacumen Platycladi polyphenol capable of reducing activity of uric acid, and a preparation method and application of the Cacumen Platycladi polyphenol. The Cacumen Platycladi polyphenol is obtained by ultra-high-pressure leaching, normal-pressure high-temperature leaching, filtration concentration and macroporous adsorption resin purification. The Cacumen Platycladi polyphenol is high in safety and high in thermal stability. A xanthine oxidase inhivitory activity test proves that the Cacumen Platycladi polyphenol has good uric acid reducing activity, and can be used for preparing functional foods with a uric acid reducing effect or assistant treatment medicines for diseases such as hyperuricemia and gout. A preparation technology is reasonable, simple and environment-friendly, and the Cacumen Platycladi polyphenol is easy to produce widely and industrially.

Compositions include vitamin C, water and a reducing sugar, result in increased stability of vitamin C. Further the addition of alcohol to aqueous vitamin C compositions increased the stability of vitamin C. Moreover, aqueous vitamin C compositions having surfactant included therein enhance the absorption of vitamin C into skin. Methods of using the stable vitamin C compositions are also described.

The invention provides an externally applied plaster and an oral medicament mainly treating bone fracture. They contain natural copper, saffron, myrrh, frankincense, panax notoginseng, dragon's blood, tortoise plastron, borneol, Taishe, ground beetles and other traditional Chinese herbal medicinal components. The externally applied plaster and the oral medicament can be used in coordination. The invention also provides a preparation method of the externally applied plaster. The plaster and the medicament provided in the invention have significant curative effects on fracture, osteomyelitis and bone tuberculosis, as well as lumbar disc herniation, cervical spondylosis, scapulohumeral periarthritis, rheumatic arthritis, traumatic injuries, breast hyperplasia and other diseases, and have the characteristics of quick effect, high cure rate, no recurrence, no toxic or side effect, convenient application and low cost, etc.

Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B (dermatan sulfate), and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, scleroderma, keloids, pulmonary fibrosis and surgical adhesions.

The invention discloses an external traditional Chinese medicine bag formula, a medicine bag and an application method thereof, and belongs to the field of traditional Chinese medicines. The externaltraditional Chinese medicine bag formula comprises the following components in parts by weight: 10-30 parts of dried ginger, 5-15 parts of mint, 10-20 parts of turmeric, 10-20 parts of radix angelicae, 5-15 parts of cassia twig, 2-10 parts of angelica sinensis, 2-10 parts of ligusticum wallichii, 2-10 parts of asarum and 50-90 parts of folium artemisiae argyi; and the traditional Chinese medicinebag prepared by using the formula has relatively strong effects of promoting blood circulation and removing blood stasis, diminishing inflammation and relieving pain, warming channels and dredging collaterals, dispelling cold and the like through synergistic interaction of all the components, the traditional Chinese medicine bag is used for promoting metabolism by virtue of hot compress for bloodcirculation, is relatively high in comfort degree and can be widely applied to the health care industry and treating for osteoarticular diseases such as cervical spondylosis and lumbar spondylosis anddeficiency-cold diseases, the traditional Chinese medicine bag is low in cost, convenient to use, high in safety, free of side effects, large in operation area, fast in effect, remarkable in curativeeffect and the like; the method is simple to operate, raw materials are easy to obtain, cost is low, and the external traditional Chinese medicine bag is suitable for market requirements in the traditional Chinese medicine and health-care industries.

The invention relates to a composition with effect of treating gout. The composition is characterized by consisting of the following ingredients in percentage by weight: 20 to 30 percent of codonopsis alpina, 20 to 30 percent of tinospora sinensis merr, 12 to 20 percent of costustoot, 12 to 20 percent of nardostachyos root and rhizome and 12 to 20 percent of northern corydalis bungeana. The composition of the invention has the effects of clearing heat and releasing toxin, eliminating swelling and stopping pain, and dispelling wind and removing dampness. The composition is mainly used for treating gout. The composition overcomes the defects that the symptoms can be cured, the root cause cannot be cured, the medicament has high toxicity, the disease is susceptible to relapse after treatment, and the total effect of the treatment is not good enough in the conventional treating method.

This invention relates to an osteogenic device for the de novo induction of bone formation in a mammal. The device contains a at least one transforming growth factor—&bgr;3 isoform and a retention matrix. The device is introduced by direct injection or surgical implantation into an area where de novo bone formation is desired and, once implanted, the retention matrix acts to retain the TGF-&bgr;3 isoform at its place of introduction and forms a scaffold for generated bone, the induction of which is promoted by the TGF-&bgr;3 isoform. The device may be used to induce bone growth where bone has been debrided in a surgical procedure and it may also be used to transform neoplastic primary and/or metastatic secondary masses into bone thus facilitating surgical debridement thereof.

The invention discloses a traditional Chinese medicine combination preparation for treating gout and a preparation method of the traditional Chinese medicine, and belongs to the technical field of traditional Chinese medicines. The effective constituents of the traditional Chinese medicine combination preparation comprise the following raw materials: chinaroot greenbrier, herba plantaginis, Chinese tulip bulb, celastrus aculeatus, laxflower pottsia roots, rhizoma polygonati, common jasminorange roots, equisetum sylvaticum, tube clematis roots or stems, folium daphnes odorae, clematis florida, cowberry leaves, ovate catalpa fruit, cortex fraxini, lycoris radiate and stevia rebaudiana. The traditional Chinese medicine combination preparation provided by the invention is reasonable in prescription, good in curative effect, convenient to use, good in absorbing effect, is free of adverse, toxic or side effects, has a good therapeutic effect on gout by clinical verifications, and is suitable for gout clinical treating and nursing popularization and application.